Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years

DOI: 10.1186/s13058-020-01340-4

Document Version
Final published version

Link to publication record in Manchester Research Explorer

Citation for published version (APA):
Brentnall, A. R., Warren, R., Harkness, E. F., Astley, S. M., Wiseman, J., Fox, J., Fox, L., Eriksson, M., Hall, P., Cuzick, J., Evans, D. G., & Howell, A. (2020). Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years. Breast cancer research : BCR, 22(1), 101. [101]. https://doi.org/10.1186/s13058-020-01340-4

Published in:
Breast cancer research : BCR

Citing this paper
Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights
Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy
If you believe that this document breaches copyright please refer to the University of Manchester’s Takedown Procedures [http://man.ac.uk/04Y6Bo] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.
Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years

Adam R. Brentnall, Ruth Warren, Elaine F. Harkness, Susan M. Astley, Julia Wiseman, Jill Fox, Lynne Fox, Mikael Eriksson, Per Hall, Jack Cuzick, D. Gareth Evans, and Anthony Howell

Abstract

Background: A decrease in breast density due to tamoxifen preventive therapy might indicate greater benefit from the drug. It is not known whether mammographic density continues to decline after 1 year of therapy, or whether measures of breast density change are sufficiently stable for personalised recommendations.

Methods: Mammographic density was measured annually over up to 5 years in premenopausal women with no previous diagnosis of breast cancer but at increased risk of breast cancer attending a family-history clinic in Manchester, UK (baseline 2010-2013). Tamoxifen (20 mg/day) for prevention was prescribed for up to 5 years in one group; the other group did not receive tamoxifen and were matched by age. Fully automatic methods were used on mammograms over the 5-year follow-up: three area-based measures (NN-VAS, Stratus, Densitas) and one volumetric (Volpara). Additionally, percentage breast density at baseline and first follow-up mammograms was measured visually. The size of density declines at the first follow-up mammogram and thereafter was estimated using a linear mixed model adjusted for age and body mass index. The stability of density change at 1 year was assessed by evaluating mean squared error loss from predictions based on individual or mean density change at 1 year.

Results: Analysis used mammograms from 126 healthy premenopausal women before and as they received tamoxifen for prevention (median age 42 years) and 172 matched controls (median age 41 years), with median 3 years follow-up. There was a strong correlation between percentage density measures used on the same mammogram in both the tamoxifen and no tamoxifen groups (all correlation coefficients > 0.8). Tamoxifen reduced mean breast density in year 1 by approximately 17–25% of the inter-quartile range of four automated percentage density measures (Continued on next page)
at increased risk of the disease in several countries [3]. Licensed for breast cancer prevention in healthy women diagnosed at an early stage, and also to slow disease chance that breast cancer will recur when it has been.

Tamoxifen is used in adjuvant settings to reduce the risk of endometrial cancer, pulmonary embolism and deep vein thrombosis. It would be hard to justify using an unstable measure of breast density as a basis to recommend individual women to stop therapy at 1 year.

The only study in the prevention setting to have shown a relationship between density change and incidence of breast cancer in healthy women receiving tamoxifen used visual assessment on a 5% point scale by a single reader [7].

In the treatment setting, several prognostic factors for breast cancer have been identified. These include classical factors such as tumour size, grade and lymph node involvement, and biomarkers including Ki67 and commercial genetic signatures such as OncotypeDX, ProSigna and EpiClin [4]. In the prevention setting, models are available to assess risk of breast cancer and may be used to help target preventive therapy with tamoxifen [5]. In both populations, there is evidence that mammographic density reduction associated with tamoxifen is a further prognostic factor [6–14]. This biomarker might help to personalise treatment and preventive therapy, suggesting different management when no reduction is seen. However, change in mammographic density associated with endocrine therapy is not currently routinely assessed nor incorporated into clinical decision-making.

An important gap in knowledge is how to measure breast density change associated with tamoxifen. Reliability is needed for baseline measurements to assess disease risk or the need for use of additional screening modalities, such as ultrasound, contrast-enhanced mammography or magnetic resonance imaging (MRI). Reliability is sometimes measured by comparing measurement error with the total variation in the sample (the ratio is equal to 1 minus the intra-class correlation coefficient). To help determine the clinical utility of breast density change associated with tamoxifen, we believe it is also important to assess the stability of measures of individual breast density change. Our definition of stability has not been used previously to test measures of breast density change, and so we introduce it next. It was developed following a so-called predictive sequential (or prequential) approach to inference [15]. This approach is more often applied to compare competing forecasting models [16]. Here, we test for lack of stability by determining whether using observed density change for a woman at 1 year is a better predictor of 2 years change than using the mean change for all women at 1 year (i.e. same prediction for all). We call any measure of density change that fails this predictive test unstable. We find it to be a worthwhile test because it would be hard to justify using an unstable measure of breast density as a basis to recommend individual women to stop therapy at 1 year.

The main aim of this study was to determine the reliability, stability and size of different measures of mammographic density change in premenopausal women receiving tamoxifen for preventive therapy, and in comparison with a group who did not receive tamoxifen. To achieve this, we compared data from two cohorts of high-risk women in Manchester, UK: (i) those enrolled into a tamoxifen-prevention study (TAM-PREV) that was designed to determine uptake of tamoxifen in the target population and to investigate the possibility that we can target treatment to women most likely to benefit, and (ii) other women of the same age attending the same family-history clinic, but without receiving tamoxifen over the same period. Our objective was to assess average change in different measures of breast density over 5 years, and to...
determine the reliability and stability of individual mammographic density change in order to potentially guide clinical decisions.

Methods

Patients

Premenopausal women with no previous diagnosis of breast cancer and at high risk of breast cancer eligible for tamoxifen for prevention were invited to join the TAM-PREV study, which was designed to study uptake and acceptance of tamoxifen. Precise eligibility criteria are given in the supplementary material. Participants in TAM-PREV were given 20 mg/day of tamoxifen, orally for a maximum 5 years. They attended yearly follow-up appointments for mammography and where adherence was monitored via self-report in person. Of the 135 women who joined TAM-PREV, \( n = 2 \) (1%) did not receive tamoxifen; \( n = 30 \) (22%) started but stopped tamoxifen within 1 year, a further \( n = 11 \) (8%), 17 (13%), 7 (5%) and 3 (2%), respectively, in 1-year intervals from 1.5 to 4.5 years; and \( n = 76 \) (56%) completed the full 5 years. A cohort consisting of women attending the same family-history clinic who did not receive tamoxifen were also enrolled and consented in the FH-Risk study. All participants had a baseline mammogram over the same epoch (2010–2013) [21].

Mammographic density

Full field digital mammography was used to screen women for breast cancer at each visit. Both raw (DICOM type ‘FOR PROCESSING’) and processed (‘FOR PRESENTATION’) mammograms of two views (medio-lateral oblique, MLO; cranial caudal, CC) of both breasts were obtained and used to measure breast density by different methods. The majority of mammograms were taken using GE machines (80%); others were on Hologic, Ims Giotto and Siemens Inspiration machines; in this analysis, only GE machines were used since one method (NN-VAS) is only designed for mammograms from this manufacturer. Four fully objective measures of breast density were computed on each of the images. They were (i) NN-VAS (neural network fitted to percentage density on visual assessment scale) version 1.0 [22], (ii) Volpara volumetric density version 1.5.2 [23], (iii) Stratus [24] and (iv) Densitas version 2.0.0 [20]. The mean of each density measure over all views and both breasts was the single measure used at each time point. Reliability of the different density measures was broadly similar, with intra-class correlation coefficients from 0.88 (Densitas) to 0.93 (Stratus) (Supplementary Table S8). To enable comparison with the results from the only study to show a relation to clinical outcome [7] in the prevention setting, we included the same visual percentage density change measure from that study as a ‘gold standard’ reference. Percentage density at baseline and first follow-up mammogram was determined visually by a single reader (RW). This was done on a semi-continuous scale between 0 and 100% in 5% increments, which is the same measure and expert reader (RW) as an earlier study from the IBIS-I trial [7]. To assess reproducibility, visual assessment was done on two separate occasions: (i) when using both cohorts and blinded to treatment allocation and order of mammograms, and (ii) on a subset of the tamoxifen cohort and unblinded to order of mammograms. This showed that visual assessment of a 10% or more percentage change was discordant for one quarter of those women assessed twice (26/100).

Study design

Up to two women in the no tamoxifen (control) group were matched to the tamoxifen cohort (TAM-PREV), based on availability of matched controls defined by age at baseline mammogram (± 1 year) and year of baseline mammogram. All women had a mammogram at entry to the study (before tamoxifen use in the tamoxifen group) and were seen annually in the family-history clinic for up to 5 years for their routine follow-up appointment by AH (median 3 years in both groups). For women in the tamoxifen group, only mammograms during active treatment were used.

Statistical analysis

Change in percentage density was the primary measure and in comparison with visually assessed percentage density change. Change in dense area and volume were assessed as secondary measures. The analysis only included time points where all automated density measures were available. This was done to ensure valid comparisons between the measures. A similar proportion of images were excluded for each method due to their internal quality control algorithms, except NN-VAS because only GE mammograms could be run (total mammograms \( n = 1798 \); exclusions: Volpara \( n = 72 \) (4%); Stratus \( n = 124 \) (7%); Densitas \( n = 101 \) (6%); NN-VAS \( n = 387 \) (22%); total exclusions \( n = 450 \) (25%)). Analysis used samples of women with mammographic density available (A) at baseline, (B) baseline and first year follow-up and (C) the subset of (B) additionally with breast density at year 2 follow-up.

Summary statistics were reported on the original breast density scale. All other analysis used transformed measures. Transformations were used to reduce skewness and improve approximation to normality. Volumetric percentage density and dense volume were natural logarithm transformed; percentage density measures square root transformed. To help make comparisons between the density methods, the transformed densities were standardised to have zero mean and unit inter-quartile range at baseline. Correlation between the density methods was
assessed between women through a weighted Pearson correlation coefficient [25]. Cutpoints for density change for automated methods were selected to aid interpretation with respect to results from the IBIS-I trial [7]: density change in automated methods was defined by a cutpoint that yielded the same number of women in the no tamoxifen group above the cutpoint as the visual 10% absolute density change method and cutpoint used in the earlier study [7].

A normal linear mixed model for each density measure was fitted by maximum likelihood [26]. Fixed effects were included for (1) intercept, (2) group (tamoxifen vs no tamoxifen), (3) age (per 5 years), (4) body mass index (per 5 kg/m²), (5) time greater than 1 year (indicator variable), (6) year for year 2 onwards, (7) interaction between terms (2) and (5) and (8) interaction between (2) and (6). Random effects at the participant level were included to allow for different trajectories for each woman for a random intercept and slope (time since baseline mammogram), which were assumed bivariate normal. The fixed effects (5) and (7) allow for a different change in density at 1 year between the groups; (6) and (8) allow for different rates of change by year thereafter. Missing body mass index was imputed using the mean. Reliability was estimated using intra-class correlation coefficients (ICCs) from the model, being defined as the estimated residual variance divided by total variance. Profile likelihood 95% confidence intervals were obtained for the model fit parameters. A non-parametric empirical bootstrap 95% confidence interval (3000 resamples) was used for the ICC statistics. In a sensitivity analysis, the model was re-fitted in the tamoxifen group alone (without fixed effects (2), (7) and (8)).

A predictive test was used to assess stability of different measures of breast density change at 1 year in women receiving tamoxifen. This compared predicting change at 2 years to be either (i) individual change at 1 year or (ii) mean density change at 1 year (i.e. the same predicted change in density for all women). Predictive ability was measured using mean squared error (MSE). This loss function is also the criterion used to fit ordinary linear regression models. The MSE of (i) relative to reference (ii) was estimated with non-parametric percentile bootstrap 95% confidence intervals.

All statistical analysis used software R 3.4.1 [27, 28]

### Results

The two cohorts were broadly comparable at baseline in analysis samples A (tamoxifen \( n = 126 \), no tamoxifen \( n = 172 \)), B (tamoxifen \( n = 94 \), no tamoxifen \( n = 112 \)) and C (tamoxifen \( n = 70 \), no tamoxifen \( n = 89 \); Fig. 1, Supplementary Tables S1-S5). The tamoxifen and no tamoxifen groups were well matched for age and had similar body mass index. Approximately one quarter in both the tamoxifen and no tamoxifen group were obese (body mass index of greater than 30 kg/m²), one quarter

---

**Fig. 1** Flow diagram with number of women showing the number of women included in analysis samples A (all women included in the study), B (those with 1 year density change) and C (those with 1 year and 2 years density change measured)
overweight (body mass index greater than 25 kg/m²), and one quarter had a BMI less than approximately 22 kg/m². Projected lifetime risk was similar, with the majority at high risk (more than 30% lifetime risk). Approximately 80% had children, and the age at first child was similar in those with children, being 27 years on average in the tamoxifen and no tamoxifen groups.

Mean percentage density differed substantially between all methods of measurement, as did the average change in percentage density between baseline and year 1 in

| Table 1: Summary statistics of density measures at baseline (T0) and year 1 (T1) in analysis sample A (all women included in the study) |
|-------------------------------|------------------|------------------|
| **Visual % blinded**          | **Tamoxifen**     | **No tamoxifen** |
| N (unk%)                      | Median (IQR, range) | Mean (SD*)       |
| Baseline                      | 125 (1%)          | 25.0 (15.0–45.0, 0.0–90.0) | 32.0 (21.7) |
| T1                            | 98 (1%)           | 20.0 (10.0–40.0, 0.0–90.0) | 26.0 (18.8) |
| T1–T0                         | 94 (1%)           | −5.0 (−13.8–0.0, −45.0–20.0) | −6.4 (9.8, −0.66) |
| **Visual % unblinded**        | **Tamoxifen**     | **No tamoxifen** |
| N (unk%)                      | Median (IQR, range) | Mean (SD)       |
| Baseline                      | 98 (22%)          | 25.0 (15.0–45.0, 0.0–95.0) | 31.3 (20.5) |
| T1                            | 96 (3%)           | 20.0 (10.0–30.0, 0.0–90.0) | 23.4 (18.0) |
| T1–T0                         | 92 (3%)           | −5.0 (−12.8–5.0, −35.0–25.0) | −8.7 (9.4, −0.92) |
| **Stratus %**                 | **Tamoxifen**     | **No tamoxifen** |
| N (unk%)                      | Median (IQR, range) | Mean (SD)       |
| Baseline                      | 126 (0%)          | 37.8 (13.5–56.8, 0.2–77.2) | 34.6 (23.6) |
| T1                            | 99 (0%)           | 27.6 (4.7–45.5, 0.1–67.4) | 27.2 (21.3) |
| T1–T0                         | 95 (0%)           | −6.2 (−12.9–0.9, −56.5–12.0) | −7.8 (9.7, −0.81) |
| **StratusDA**                 | **Tamoxifen**     | **No tamoxifen** |
| N (unk%)                      | Median (IQR, range) | Mean (SD)       |
| Baseline                      | 126 (0%)          | 47.8 (17.2–64.7, 0.2–167.6) | 46.5 (34.8) |
| T1                            | 99 (0%)           | 29.9 (9.1–47.7, 0.2–128.1) | 34.2 (28.9) |
| T1–T0                         | 95 (0%)           | −6.0 (−11.0–3.0, −21.0–34.0) | −10.8 (−19.2–3.0, −75.5–20.3) |
| **Densitas %**                | **Tamoxifen**     | **No tamoxifen** |
| N (unk%)                      | Median (IQR, range) | Mean (SD)       |
| Baseline                      | 126 (0%)          | 41.0 (32.0–49.5, 12.0–73.0) | 41.2 (12.9) |
| T1                            | 99 (0%)           | 38.0 (29.0–47.0, 13.0–66.0) | 37.7 (12.3) |
| T1–T0                         | 95 (0%)           | −5.0 (−8.0–1.5, −21.0–34.0) | −4.3 (7.0, −0.62) |
| **DensitasDA**                | **Tamoxifen**     | **No tamoxifen** |
| N (unk%)                      | Median (IQR, range) | Mean (SD)       |
| Baseline                      | 126 (0%)          | 44.0 (32.2–57.0, 15.0–131.0) | 43.7 (22.3) |
| T1                            | 99 (0%)           | 36.0 (27.5–49.5, 15.0–143.0) | 41.4 (20.9) |
| T1–T0                         | 95 (0%)           | −6.0 (−11.0–3.0, −35.0–103.0) | −5.8 (14.0, −0.42) |
| **Volpara %**                 | **Tamoxifen**     | **No tamoxifen** |
| N (unk%)                      | Median (IQR, range) | Mean (SD)       |
| Baseline                      | 126 (0%)          | 8.6 (5.4–15.7, 2.2–31.4) | 11.0 (6.8) |
| T1                            | 99 (0%)           | 7.5 (4.7–13.0, 2.1–27.8) | 9.3 (5.8) |
| T1–T0                         | 95 (0%)           | −0.9 (−2.3–0.2, −9.8–4.6) | −1.4 (2.5, −0.56) |
| **VolparaDV**                 | **Tamoxifen**     | **No tamoxifen** |
| N (unk%)                      | Median (IQR, range) | Mean (SD)       |
| Baseline                      | 126 (0%)          | 61.4 (43.9–86.2, 17.6–189.9) | 69.4 (36.2) |
| T1                            | 99 (0%)           | 49.7 (35.9–67.0, 17.5–173.1) | 55.3 (27.3) |
| T1–T0                         | 95 (0%)           | −11.0 (−21.6–2.7, −74.2–26.5) | −14.2 (16.3, −0.87) |
| **NN-VAS %**                  | **Tamoxifen**     | **No tamoxifen** |
| N (unk%)                      | Median (IQR, range) | Mean (SD)       |
| Baseline                      | 126 (0%)          | 41.1 (29.7–54.5, 7.1–76.8) | 42.0 (16.3) |
| T1                            | 99 (0%)           | 37.4 (23.6–47.0, 5.3–73.7) | 36.9 (15.0) |
| T1–T0                         | 95 (0%)           | −5.3 (−8.8–2.0, −24.2–18.1) | −5.3 (5.8, −0.90) |

*DA dense area, DV dense volume, IQR inter-quartile range, SD standard deviation, unk unknown
*T1–T0 for tamoxifen group statistic is mean (SD, mean/SD)
the tamoxifen group. The mean absolute percent density change in women receiving tamoxifen ranged from approximately 1.4% (Volpara) to 7.8% (Stratus), while there was very little change during the first year in the no tamoxifen group (Table 1). However, there was a strong correlation between different percentage density measures in both the tamoxifen and no tamoxifen groups (all repeated-measures correlation coefficient > 0.8, Table 2 and Supplementary Table S6, Supplementary Figure S1), and on a standardised scale, the average change was similar for different measures of breast density. Total volume or area was negatively correlated with percentage density partly because it is the denominator of percentage density.

Figure 2 shows an initial decline at 1 year followed by a sustained decrease thereafter in the tamoxifen group. This was also seen from age and BMI-adjusted estimates of density change. The estimated yearly decrease in density from year 2 was estimated to range from approximately 2 to 7% of IQR change per year depending on the density measure. The model fit was similar for each measure of breast density (Supplementary Tables S7 and S8). In a model fitted to the tamoxifen group alone, all methods except percentage density by Densitas had a moderate correlation between the random intercept and slope (approximately −0.3 to −0.6, Supplementary Tables S9, S10), indicating a larger tamoxifen-induced decrease in breast density for those with higher breast density at baseline.

Results from automated methods of density change were compared to visual assessment as the gold standard method. For a similar proportion of women who did not receive tamoxifen (approximately 16%), the automated methods identified a greater proportion of women in the tamoxifen group with change above their high cutpoint than visual assessment based on a 10% threshold (approximately 60% for automated compared with 37% for visual; Table 3). Of the 26 women with more than 10% density change based on visual assessment in the tamoxifen group, n = 18 (Stratus and Volpara) to n = 20 (Densitas and NN-VAS) were identified by automated methods. The automated measures all agreed on change at year 1 for n = 19 (27%) of 70 women, but only 6 (9%) of 70 women at first follow-up did not fall into a high change group by any of the measures (Supplementary Table S11).

While similar average changes were detected, individual breast density change at 1 year was not stable for 2 years change using any measure. Predicting each woman’s density change at 2 years to be that observed at 1 year had between approximately 60 to 300% greater error than using the overall mean density change at 1 year (Table 4). The lack of stability in measurement of individual breast density change was further indicated by disagreement in women above a threshold using the same density measure of change based on change at 1 year or 2 years for approximately 40% women (Supplementary Table S12).

### Discussion
This study investigated five measures of mammographic density in women receiving tamoxifen preventive therapy, compared with similar women who did not, over up to 5 years. The primary focus was on change at 1 year. There were two main findings.

Firstly, all breast density measures revealed a large average change in density among women receiving tamoxifen for prevention over the first year, and a continued average decline thereafter. The size of these changes in comparison with those without tamoxifen was consistent between the different measures when assessed on standardised scales. This appears to be the first report in a preventive setting to demonstrate there is a continued decline in

### Table 2
Repeated measures correlation between density measures in the group of women that did not receive tamoxifen from analysis sample A (all women included in the study)

|          | Visual % | Stratus % | Densitas % | Volpara % | Stratus DA | Densitas DA | Volpara DV | Densitas BA | Volpara TV |
|----------|----------|-----------|------------|------------|------------|-------------|------------|-------------|------------|
| Stratus %| 0.85     |           |            |            |            |             |            |             |            |
| Densitas %| 0.87     | 0.90      |            |            |            |             |            |             |            |
| Volpara % | 0.89     | 0.92      | 0.92       |            |            |             |            |             |            |
| Stratus DA| 0.68     | 0.86      | 0.74       | 0.67       |            |             |            |             |            |
| Densitas DA| 0.12     | 0.14      | 0.18       | −0.02      | 0.57       |             |            |             |            |
| Volpara DV| 0.40     | 0.41      | 0.44       | 0.28       | 0.73       | 0.81        |            |             |            |
| Densitas BA| −0.45   | −0.48     | −0.51      | −0.62      | −0.03      | 0.74        | 0.42       |             |            |
| Volpara TV| −0.49   | −0.52     | −0.49      | −0.69      | −0.05      | 0.64        | 0.50       | 0.88        |            |
| NNVAS %  | 0.89     | 0.93      | 0.92       | 0.91       | 0.83       | 0.25        | 0.52       | −0.39       | −0.43      |

**DA** dense area, **DV** dense volume, **BA** breast area, **TV** total volume, **NNVAS** neural network visual assessment score
mammographic density beyond the first year of receiving tamoxifen.

Secondly, even if breast density change over 1 year is a prognostic or predictive biomarker for women receiving tamoxifen for breast cancer prevention, current measures of mammographic density might not measure change in breast density at 1 year with sufficient stability for clinical use. The analysis indicates that if a clinician advises a woman that her breast density has changed by the amount measured at 1 year, then on aggregate this may be up to 300% worse (using mean squared error) as a prediction of her 2 years breast density change than advising all women that their density is likely to have changed by the same amount. It therefore appears that mammographic density change at 1 year is not stable using current technology.
Table 3 Number of women with a decrease in breast density greater than a cutpoint using analysis sample C (women with density change measured at 1 year and 2 years)

| Measure | Cutpoint* | Tamoxifen | No tamoxifen | Decrease difference (95% CI) |
|---------|-----------|-----------|--------------|-----------------------------|
| (a) Visual % | | | | |
| T1–T0  | 0.0 | −10.0 | 24 (34%) | 26 (37%) | 57 (64%) | 18 (20%) | 14 (16%) | 21% (7–36%) |
| (b) Stratus % | | | | |
| T1–T0  | 0.0 | −4.6 | 10 (14%) | 14 (20%) | 44 (63%) | 45 (51%) | 30 (34%) | 14 (16%) | 47% (32–62%) |
| T2–T0  | 0.0 | −4.6 | 9 (13%) | 14 (20%) | 47 (67%) | 50 (56%) | 20 (22%) | 19 (21%) | 46% (31–61%) |
| (c) Densitas % | | | | |
| T1–T0  | 0.0 | −3.6 | 9 (13%) | 17 (24%) | 44 (63%) | 48 (54%) | 27 (30%) | 14 (16%) | 47% (32–62%) |
| T2–T0  | 0.0 | −3.6 | 7 (10%) | 23 (33%) | 40 (57%) | 47 (53%) | 24 (27%) | 18 (20%) | 37% (21–52%) |
| (d) Volpara % | | | | |
| T1–T0  | 0.0 | −1.4 | 14 (20%) | 17 (24%) | 39 (56%) | 45 (51%) | 30 (34%) | 14 (16%) | 40% (25–53%) |
| T2–T0  | 0.0 | −1.4 | 5 (7%) | 19 (27%) | 46 (66%) | 48 (54%) | 22 (25%) | 19 (21%) | 44% (29–60%) |
| (e) NNVAS % | | | | |
| T1–T0  | 0.0 | −4.4 | 8 (11%) | 24 (34%) | 38 (54%) | 36 (40%) | 39 (44%) | 14 (16%) | 39% (23–54%) |
| T2–T0  | 0.0 | −4.4 | 10 (14%) | 14 (20%) | 46 (66%) | 47 (53%) | 29 (33%) | 13 (15%) | 51% (37–66%) |

T0, density at entry; T1, density at 1 year; T2, density at 2 year; no change, density change greater than or equal to this is classed as no change; change, density change less than or equal to this is classed as decrease; the intermediate category is density in between these; decrease difference, absolute difference in density change percentage between tamoxifen and no tamoxifen groups.

*For automated methods, the cutpoints shown are for differences in transformed percentage density (×10), being the natural logarithm for Volpara and square root for the other methods.

The standardised and transformed scales used alter interpretation of the density change on the original scale. The change in logarithm volumetric density is equivalent to a relative change (ratio). The difference between square root percentage density is less interpretable, but is partly justified because on these transformed and standardised scales all measures showed similar average effects of tamoxifen through time, even though they are all different algorithms. There were some apparent subtle differences, such as Stratus showing a smaller decrease in standardised density than the others (Fig. 2, Supplementary Table S7), but we are cautious about overinterpretation of such differences. For example, we would observe a different point estimate if we had applied a different transformation than square root for Stratus (c.f. Supplementary Figure S1).

Overall results across the different density methods were similar and in agreement with a gold standard method based on visual assessment. The similar average effects and reliability (ICCs) suggest merit for all in clinical studies designed to measure average change in breast density. The similarity between methods is striking because there are substantial differences between how the algorithms function. The volumetric method (Volpara) is based on a medical physics model. The other methods use machine learning algorithms. Stratus includes an algorithm to align images so that density change is more stable. NN-VAS was trained on visual assessment of raw unprocessed images from the PROCAS study [22], which was from the same Manchester setting as the present study. Densitas uses processed DICOM files.

Despite agreement between measures on average, we found that density change at an individual level was not stable. This might be caused by other factors than the breast density algorithms. Alternative explanations include possible natural variation in breast density, such as during the menstrual cycle. Another possible explanation is variability in the way mammography might be done through time. Further research could try to iden-

Table 4 Mean squared error (×100) in analysis sample C (women with density measured at 1 year and 2 years) (relative performance (95% CI)) for predicting density change at 2 years, using mean density change at year 1 (REF = reference predictor) or individual observed density change at year 1

| Measure | Stratus % | Densitas % | Volpara % | NNVAS % |
|---------|-----------|------------|-----------|---------|
| Mean change T0–T1 | 6.0 (REF) | 21.4 (REF) | 4.2 (REF) | 12.0 (REF) |
| Individual change T0–T1 | 14.5 (2.4 (1.6 to 3.3)) | 65.9 (3.1 (1.8 to 3.9)) | 10.0 (2.4 (1.8 to 3.0)) | 19.7 (1.6 (1.3 to 2.3)) |

T0, entry; T1, follow-up at 1 year
tify how to make density change measures more stable. The net result of this is that in settings that are similar to the current study, it seems inappropriate to recommend women to end tamoxifen after a year of use, solely on the basis that their breast density has not decreased. Lack of change at 1 year might be due to measurement error. On the flip side, if a woman has observed a large breast density change at 1 year, then adherence could be encouraged if findings from the single research study on breast density change and breast cancer incidence are replicated in the future [7]. This is because they suggest that, on average, a group of women with larger density changes appear to have better prognosis. Similar reasoning would apply in a tamoxifen treatment context.

This study has a number of limitations. Firstly, due to the study size, we were unable to link change in density due to tamoxifen with subsequent risk reductions in breast cancer. Secondly, treatment was not randomised between the tamoxifen and no tamoxifen groups. Thirdly, we were unable to assess what happened to breast density once tamoxifen stopped being prescribed. Fourthly, weight and menopausal status were not monitored through time for all women. Knowing about these changes through time would enable a more precise determination of breast density change since they are established to be associated with breast density.

Strengths of this study include that compliance was actively monitored yearly, and we excluded breast density after drug use ended. This ensured an accurate measure of the effect of tamoxifen on mammographic density, but is also important for prognosis studies of breast density change. For example, a potential bias in studies of breast density change and prognosis in women who have been recommended to receive tamoxifen is that it could partly reflect compliance: those who benefit are those who received the drug.

In summary, on the aggregate level (e.g. evaluating an entire population or clinical trial), tamoxifen-associated density declines may provide an important signal (e.g. for indicating tamoxifen effectiveness) but this signal appears to be ‘too noisy’ at the individual level to use it to make clinical recommendations. We expect these findings would be generalisable to treatment settings as well, but further studies are warranted to test this hypothesis.

Conclusions
Our study provides the first analysis in a tamoxifen-prevention setting of longitudinal breast density measured yearly over up to 5 years, and includes fully automated measures that have not previously been examined in a tamoxifen prevention or treatment context. The data provide important information on the reliability, stability and size of breast density changes from different methods used to measure breast density. All measures showed a large average decline in breast density after 1 year of tamoxifen, and a continued decline in mammographic density beyond the first year of receiving tamoxifen. All methods had relatively high intra-class correlation coefficients (approximately 0.9) indicating a good degree of reliability. However, breast density change at 1 year did not appear to be sufficiently stable to inform personalisation of clinical decisions on the basis of a woman’s observed breast density change. These findings will be important to clinicians and their patients undergoing or considering endocrine therapy, as well as regulators and ethics boards considering trials of products that require information on the reliability and stability of mammographic density reductions as an endpoint.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13058-020-01340-4.

Additional file 1: Supplementary material

Acknowledgements
We thank all the women who took part and contributed to this research.

Authors’ contributions
Conception of work: AH and DGE; study design: AH, DGE and SMA; data acquisition: AH, RW, EFH, JW, JF, LF, SA, ME, PH and DGE; data analysis: ARB, EFH and AH; data interpretation: ARB, EFH, AH, JC and DGE; drafted the work: ARB, JC and AH. All authors approved the submitted version and have agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved; and the resolution documented in the literature.

Funding
This article presents independent research funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit programme (Grant number: PB-PG-0110-21342). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. It was also supported by Genesis Breast Cancer Prevention (Grant number: GA69-001/GA10-002). DGE, EFH, SA and AH are supported by the NIHR Manchester Biomedical Research Centre (ES-BRC-1215-20007). DGE is an NIHR senior investigator. ARB and JC were supported by Cancer Research UK (Grant number: C569/A16891). Funders had no role in the design of the study and collection, analysis and interpretation of data or in writing the manuscript.

Availability of data and materials
The dataset used and analysed during the current study is available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Women in both FH-Risk (no tamoxifen) and TAM-PREV (tamoxifen) cohorts provided informed written consent for use of their data and mammograms for this research. FH-Risk was approved by Greater Manchester Central Research Ethics committee, Ref: 10/H1008/24; TAM-PREV approved by Greater Manchester West Research Ethics Committee, Ref: 11/H1014/4.

Consent for publication
Not applicable.

Competing interests
Prof Evans and Howell report receiving consultancy fees from AstraZeneca. Prof Cuzick has received funding from Sanofi-Aventis and AstraZeneca, and is a paid member of a speaker’s bureau for AstraZeneca. Prof Cuzick and Dr
Brentnall report receiving royalty payments through Cancer Research UK for commercial use of the Tyrer–Cuzick algorithm to assess breast cancer risk. None of the other authors report any conflict of interest.

Author details
1. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK. 2. Department of Radiology, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK. 3. Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. 4. Preventive Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, M23 9LT, UK. 5. Manchester Breast Centre, Manchester Cancer Research Centre, University of Manchester, Manchester, M20 4BX, UK. 6. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 7. NW Genomic Laboratory Hub, Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, M13 9WL, UK. 8. Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. 9. Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PL, UK.

Received: 17 February 2020 Accepted: 10 September 2020

Published online: 29 September 2020

References
1. Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SRD, Korde LA, Khatchaterian JL, Mehta RS, Muss HB, Burstein HJ. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016;34(25):3069–103.
2. Early Breast Cancer Trialists' Collaborative Group, Davies C, Godwin J, Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Early Breast Cancer Trialists' Collaborative Group. Novel 18-gen signature for predicting relapse in ER-positive, HER2-negative breast cancer. Breast Cancer Res. 2018;20(1):23.
3. Highnam R, Brady S, Yaffe M, Karssemeijer N, Harvey J. Robust Breast Densitometry: An introduction to mammographic breast density measurement. Breast. 2019;47:62–76.
4. Nyante SJ, Sherman ME, Pfeiffer RM, de Gonzales AB, Brinton LA, Bowles EA, Hoover RN, Glass A, Gierach GL. Longitudinal change in mammographic density among ER-positive breast cancer patients using tamoxifen. Cancer Epidemiol Biomark Prev. 2016;25(1):212–6.
5. Hrushka CB, Wu FF, Winham SJ, Miglioretti DL, Norman AO, Heine JJ, Shepherd J, Pankratz VS, Vachon CM, Kerlikowske K. Longitudinal changes in volumetric breast density with tamoxifen and aromatase inhibitors. Cancer Epidemiol Biomark Prev. 2017;26(6):930–7.
6. Cuzick J, Hausenblas H, spaghetti-like plots and the review of statistical significance. J Natl Cancer Inst. 2013;105(5):368–103.
7. VanNess JG, Finkelstein ME, Wang J, Gao Q, Cuzick J, Dowsett M. Novel 18-gene signature for predicting recurrence in estrogen receptor-positive premenopausal breast cancer patients. Breast Cancer Res Treat. 2013;142(3):559–67.
8. Jetter G, Humphreys K, Egan J, Czene K, Hall P. Tissue factor expression and risk of contralateral breast cancer - a case-control study. Breast Cancer Res. 2013;15(4):57.
9. van Nersen JH, Beez LVAM, Seynaeve C, Putter H, Sramek A, Lardenoije S, Dujm-de Carpentier M, Van Rongen I, Nortier JWR, Zonderland HM, van de Velde CJH. Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis. Acta Oncol. 2015;54(3):349–60.
10. David AP. Present position and potential developments: some personal views statistical theory the sequential approach. J R Stat Soc A Gen. 1984;147(2):279–90.
11. Brentnall AR, Crowd J, Hand DJ. Predictive–sequential forecasting system development for cash machine stocking. Int J Forecast. 2010;26(4):764–76.
12. Nyante SJ, Sherman ME, Pfeiffer RM, de Gonzales AB, Brinton LA, Bowles EA, Hoover RN, Glass A, Gierach GL. Longitudinal change in mammographic density among ER-positive breast cancer patients using tamoxifen. Cancer Epidemiol Biomark Prev. 2016;25(1):212–6.
13. Gennaro R, Scott CG, Jensen MR, Ma L, Brandt K, Mahmoudzadeh AP, Malkov S, Whaley DH, Hrushka CB, Wu FF, Winham SJ, Miglioretti DL, Norman AD, Heine JJ, Shepherd J, Pankratz VS, Vachon CM, Kerlikowske K. Longitudinal changes in volumetric breast density with tamoxifen and aromatase inhibitors. Cancer Epidemiol Biomark Prev. 2017;26(6):930–7.
14. Cuzick J, He W, Eriksson M, Humphreys K, Bergh J, Hall P, Czene K. Adjuvant therapy and mammographic density changes in women with breast cancer. JNCI Cancert. 2018;102(4):771–84.
15. Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Pashayan B, Peto R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.
16. Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Pashayan B, Peto R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.
17. Nyante SJ, Sherman ME, Pfeiffer RM, de Gonzales AB, Brinton LA, Bowles EA, Hoover RN, Glass A, Gierach GL. Longitudinal change in mammographic density among ER-positive breast cancer patients using tamoxifen. Cancer Epidemiol Biomark Prev. 2016;25(1):212–6.
18. Engmann NJ, Scott CG, Jensen MR, Ma L, Brandt K, Mahmoudzadeh AP, Malkov S, Whaley DH, Hrushka CB, Wu FF, Winham SJ, Miglioretti DL, Norman AD, Heine JJ, Shepherd J, Pankratz VS, Vachon CM, Kerlikowske K. Longitudinal changes in volumetric breast density with tamoxifen and aromatase inhibitors. Cancer Epidemiol Biomark Prev. 2017;26(6):930–7.
19. Cuzick J, Hausenblas H, spaghetti-like plots and the review of statistical significance. J Natl Cancer Inst. 2013;105(5):368–103.
20. VanNess JG, Finkelstein ME, Wang J, Gao Q, Cuzick J, Dowsett M. Novel 18-gene signature for predicting recurrence in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer Res. 2018;20(1):23.
21. van Nersen JH, Beez LVAM, Seynaeve C, Putter H, Sramek A, Lardenoije S, Dujm-de Carpentier M, Van Rongen I, Nortier JWR, Zonderland HM, van de Velde CJH. Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis. Acta Oncol. 2015;54(3):349–60.
22. David AP. Present position and potential developments: some personal views statistical theory the sequential approach. J R Stat Soc A Gen. 1984;147(2):279–90.
23. Brentnall AR, Crowd J, Hand DJ. Predictive–sequential forecasting system development for cash machine stocking. Int J Forecast. 2010;26(4):764–76.
24. Nyante SJ, Sherman ME, Pfeiffer RM, de Gonzales AB, Brinton LA, Bowles EA, Hoover RN, Glass A, Gierach GL. Longitudinal change in mammographic density among ER-positive breast cancer patients using tamoxifen. Cancer Epidemiol Biomark Prev. 2016;25(1):212–6.
25. Gennaro R, Scott CG, Jensen MR, Ma L, Brandt K, Mahmoudzadeh AP, Malkov S, Whaley DH, Hrushka CB, Wu FF, Winham SJ, Miglioretti DL, Norman AD, Heine JJ, Shepherd J, Pankratz VS, Vachon CM, Kerlikowske K. Longitudinal changes in volumetric breast density with tamoxifen and aromatase inhibitors. Cancer Epidemiol Biomark Prev. 2017;26(6):930–7.
26. Cuzick J, Hausenblas H, spaghetti-like plots and the review of statistical significance. J Natl Cancer Inst. 2013;105(5):368–103.
27. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017. https://www.R-project.org/.
28. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67(1):1–48.

Publisher’s Note
Springer Nature remainsneutral with regard to jurisdictional claims in published maps and institutional affiliations.